AR054435A1 - Agente para profilaxis o terapia contra la depresion o desorden de ansiedad - Google Patents
Agente para profilaxis o terapia contra la depresion o desorden de ansiedadInfo
- Publication number
- AR054435A1 AR054435A1 ARP060101310A ARP060101310A AR054435A1 AR 054435 A1 AR054435 A1 AR 054435A1 AR P060101310 A ARP060101310 A AR P060101310A AR P060101310 A ARP060101310 A AR P060101310A AR 054435 A1 AR054435 A1 AR 054435A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- anxiety
- profilaxis
- disorder
- therapy against
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940080818 propionamide Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente provee un agente para profilaxis o terapia para desordenes de depresion o ansiedad, que comprende (S)-N-[2-(1,6,7,8- tetrahidro-2H-inden[5,4-b]furan-8-il)etil]propionamida. Composicion farmacéutica, método de tratamiento y uso.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005107674 | 2005-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054435A1 true AR054435A1 (es) | 2007-06-27 |
Family
ID=37073564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101310A AR054435A1 (es) | 2005-04-04 | 2006-04-03 | Agente para profilaxis o terapia contra la depresion o desorden de ansiedad |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090042861A1 (es) |
| EP (1) | EP1867641A4 (es) |
| JP (1) | JP5259181B2 (es) |
| KR (1) | KR20070118103A (es) |
| CN (1) | CN101189219A (es) |
| AR (1) | AR054435A1 (es) |
| AU (1) | AU2006231752B2 (es) |
| BR (1) | BRPI0607684A2 (es) |
| CA (1) | CA2602267A1 (es) |
| CL (1) | CL2009000980A1 (es) |
| CR (1) | CR9385A (es) |
| GE (1) | GEP20105001B (es) |
| IL (1) | IL186049A0 (es) |
| MA (1) | MA29677B1 (es) |
| MY (1) | MY142214A (es) |
| NO (1) | NO20075599L (es) |
| NZ (1) | NZ561677A (es) |
| PE (1) | PE20061355A1 (es) |
| RU (1) | RU2413510C2 (es) |
| TW (1) | TWI391132B (es) |
| UA (1) | UA89397C2 (es) |
| WO (1) | WO2006107019A1 (es) |
| ZA (1) | ZA200708445B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101983193B (zh) * | 2008-01-31 | 2014-03-12 | 武田药品工业株式会社 | 注意缺陷/多动障碍的预防或治疗剂 |
| US8426461B2 (en) | 2011-01-17 | 2013-04-23 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| KR20140014134A (ko) | 2011-01-17 | 2014-02-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 구강내 분산정 |
| EP2765985A1 (en) * | 2011-10-14 | 2014-08-20 | Takeda Pharmaceutical Company Limited | Orally dispersible tablet |
| CN102718675B (zh) * | 2012-06-07 | 2015-03-25 | 上海右手医药科技开发有限公司 | 阿戈美拉汀甲磺酸复合物及其制备方法 |
| RU2571546C1 (ru) * | 2014-07-14 | 2015-12-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ дифференцированной диагностики и терапии синдрома ночной еды |
| EP3628316A4 (en) | 2017-03-30 | 2021-04-14 | Penello Temporão, José Eduardo | MULTI-VITAMIN COMPOSITION TO IMPROVE VERB FLUIDITY AND REDUCE SYMPTOMS OF PERFORMANCE ANXIETY AND ITS PREPARATION PROCESS |
| CN108451917A (zh) * | 2018-03-22 | 2018-08-28 | 仁和堂药业有限公司 | 高稳定性米安色林制剂的制备方法 |
| CN113908165A (zh) * | 2020-07-10 | 2022-01-11 | 上海日馨医药科技股份有限公司 | 一种药物组合物及其应用 |
| WO2025018810A1 (ko) * | 2023-07-18 | 2025-01-23 | 주식회사 지오비스타 | 동물에 대한 정신질환 또는 행동장애의 예방 또는 치료용 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
| SG67930A1 (en) * | 1994-06-10 | 1999-10-19 | Smithkline Beecham Plc | Benzopyrans and their use as therapeutic agents |
| US5780470A (en) * | 1995-06-02 | 1998-07-14 | Bristol-Myers Squibb Company | Melatonergic indanyl piperazines |
| JP2884153B2 (ja) * | 1996-03-08 | 1999-04-19 | 武田薬品工業株式会社 | 三環性化合物、その製造法および剤 |
| US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
| SK283970B6 (sk) * | 1996-03-08 | 2004-06-08 | Takeda Chemical Industries, Ltd. | Tricyklické zlúčeniny, spôsob výroby a farmaceutický prípravok ich obsahujúci |
| JP3509637B2 (ja) * | 1998-06-09 | 2004-03-22 | 武田薬品工業株式会社 | 睡眠障害予防治療剤 |
| EP1100508B8 (en) * | 1998-06-09 | 2004-01-07 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders |
| AU6634201A (en) * | 2000-06-27 | 2002-01-08 | Taisho Pharmaceutical Co Ltd | Remedial agent for anxiety neurosis or depression and piperazine derivative |
| US6589978B2 (en) * | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| JP2005516891A (ja) * | 2001-09-13 | 2005-06-09 | シェーリング コーポレイション | アデノシンA2aレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ |
| US20070088079A1 (en) * | 2005-09-20 | 2007-04-19 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for sleep disorder |
-
2006
- 2006-04-03 KR KR1020077022636A patent/KR20070118103A/ko not_active Ceased
- 2006-04-03 MY MYPI20061491A patent/MY142214A/en unknown
- 2006-04-03 CN CNA2006800197795A patent/CN101189219A/zh active Pending
- 2006-04-03 NZ NZ561677A patent/NZ561677A/en not_active IP Right Cessation
- 2006-04-03 PE PE2006000359A patent/PE20061355A1/es not_active Application Discontinuation
- 2006-04-03 UA UAA200710985A patent/UA89397C2/ru unknown
- 2006-04-03 US US11/918,034 patent/US20090042861A1/en not_active Abandoned
- 2006-04-03 AU AU2006231752A patent/AU2006231752B2/en not_active Ceased
- 2006-04-03 ZA ZA200708445A patent/ZA200708445B/xx unknown
- 2006-04-03 BR BRPI0607684-0A patent/BRPI0607684A2/pt not_active IP Right Cessation
- 2006-04-03 TW TW095111740A patent/TWI391132B/zh not_active IP Right Cessation
- 2006-04-03 GE GEAP200610302A patent/GEP20105001B/en unknown
- 2006-04-03 JP JP2007511227A patent/JP5259181B2/ja not_active Expired - Fee Related
- 2006-04-03 EP EP06730995A patent/EP1867641A4/en not_active Withdrawn
- 2006-04-03 RU RU2007140986/15A patent/RU2413510C2/ru not_active IP Right Cessation
- 2006-04-03 CA CA002602267A patent/CA2602267A1/en not_active Abandoned
- 2006-04-03 AR ARP060101310A patent/AR054435A1/es not_active Application Discontinuation
- 2006-04-03 WO PCT/JP2006/307047 patent/WO2006107019A1/ja not_active Ceased
-
2007
- 2007-09-18 IL IL186049A patent/IL186049A0/en unknown
- 2007-09-18 CR CR9385A patent/CR9385A/es unknown
- 2007-10-25 MA MA30311A patent/MA29677B1/fr unknown
- 2007-11-05 NO NO20075599A patent/NO20075599L/no not_active Application Discontinuation
-
2009
- 2009-04-24 CL CL2009000980A patent/CL2009000980A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR9385A (es) | 2007-12-07 |
| IL186049A0 (en) | 2008-02-09 |
| WO2006107019A1 (ja) | 2006-10-12 |
| EP1867641A1 (en) | 2007-12-19 |
| JPWO2006107019A1 (ja) | 2008-09-25 |
| PE20061355A1 (es) | 2007-01-15 |
| RU2007140986A (ru) | 2009-05-20 |
| AU2006231752B2 (en) | 2012-03-01 |
| AU2006231752A1 (en) | 2006-10-12 |
| RU2413510C2 (ru) | 2011-03-10 |
| MA29677B1 (fr) | 2008-08-01 |
| TWI391132B (zh) | 2013-04-01 |
| UA89397C2 (ru) | 2010-01-25 |
| GEP20105001B (en) | 2010-06-10 |
| US20090042861A1 (en) | 2009-02-12 |
| CA2602267A1 (en) | 2006-10-12 |
| MY142214A (en) | 2010-11-15 |
| NZ561677A (en) | 2011-02-25 |
| JP5259181B2 (ja) | 2013-08-07 |
| KR20070118103A (ko) | 2007-12-13 |
| NO20075599L (no) | 2007-12-19 |
| TW200719885A (en) | 2007-06-01 |
| BRPI0607684A2 (pt) | 2009-09-22 |
| EP1867641A4 (en) | 2010-01-13 |
| ZA200708445B (en) | 2009-03-25 |
| CN101189219A (zh) | 2008-05-28 |
| CL2009000980A1 (es) | 2009-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0418029A (pt) | formulação de anticorpos cd40 e métodos | |
| MX2009013989A (es) | Terapia en combinacion para depresion. | |
| BR0316203A (pt) | Uso de um agente antialérgico e um esteróide para tratar rinite alérgica | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| AR043188A1 (es) | Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias | |
| ECSP11010975A (es) | Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales | |
| CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
| CL2007003827A1 (es) | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. | |
| BRPI0513812B8 (pt) | método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical | |
| BRPI0817482B8 (pt) | uso de um anticorpo do receptor da interleucina-6 (il-6) no tratamento da doença do enxerto versus hospedeiro (gvhd) | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| BRPI0510094A (pt) | uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos | |
| CR9385A (es) | Agente preventivo o terapeutico para el desorden de la depresion o la ansiedad | |
| JO3440B1 (ar) | استخدام الأغوميلاتين في تحضير علاجات لمداولة اضطرابات القلق العام. | |
| BR0107667A (pt) | Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| BRPI0718469A2 (pt) | Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto. | |
| BR0201524A (pt) | Tratamento de combinação para ansiedade e depressão | |
| BR0210650A (pt) | Tablete, e, uso do mesmo | |
| BRPI0712561B8 (pt) | Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida | |
| BR0311903A (pt) | Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico | |
| BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
| BRPI0411324A (pt) | composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes | |
| BRPI0411175A (pt) | combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão | |
| BRPI0411174A (pt) | combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |